| 摘要 |
FIELD: medicine.SUBSTANCE: invention refers to medicine and represents a method for prediction of response of oncological patient with non-Hodgkin's lymphoma to anticancer therapy, including bortezomib and rituximab, characterized by that the method involves determination of level or amount of first prognostic factor and determination of presence or amount of second prognostic factor, wherein low level of CD68 or polymorphism of PSMB1 (P11A) correlates with, at least, one positive result. Invention also relates to a diagnostic kit for detecting oncological patients with non-Hodgkin's lymphoma, which are candidates for treating cancer with bortezomib and rituximab, as well as method of treating cancer in oncological patients with non-Hodgkin's lymphoma.EFFECT: invention implementation enables predicting positive response of oncology patient to combination therapy of bortezomib and rituximab.7 cl, 5 ex, 25 tbl, 8 dwg |
